CompletedNCT04292197
A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers
Medication studyAges 18–55AustraliaAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- PerthSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: April 14, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 108
- Sponsor
- Definium Therapeutics US, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Australia
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT04292197
- Official title
Show the full official title
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single/Multiple Day Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 18- Methoxycoronaridine (18-MC HCl) Administered Orally to Normal Healthy Volunteers
Get this study by email
Recruitment & locations
CompletedPerth
Questions about this study
Who is behind this study?
The study sponsor is Definium Therapeutics US, Inc.
Did this study involve medication?
Yes. The study involved medication, including 18-MC Compound.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to explore more studies?
Explore studiesRelated studies
A Pharmacokinetic and Safety Study of the Chrono Nicotine Replacement Therapy System in male smokers.
A randomised controlled trial of unsupervised buprenorphine-naloxone versus wait list contol for heroin addiction